{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:00:18Z","timestamp":1792202418558,"version":"4.4.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    NUT carcinoma (NC) is an extremely rare, aggressive malignancy characterized by chromosomal rearrangements in the\n                    <jats:italic>NUTM1<\/jats:italic>\n                    (nuclear protein in testis) gene. It usually affects younger patients with a median age of diagnosis at 23 years old. The mainstay of treatment consists of combination chemotherapy, surgical resection, and high dose radiation. However, prognosis remains dismal with reported median overall survival of 6.7 months. Literature reporting on use of immunotherapy in head and neck NC is limited. Prolonged remission without aggressive multimodality therapy is rare. We report a case of a 87-year-old woman with metastatic sinonasal NC treated with palliative radiotherapy and pembrolizumab who achieved sustained response 2 years from diagnosis.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2024.1412070","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:32:35Z","timestamp":1736209955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: Long term remission of metastatic sinonasal NUT carcinoma after palliative radiotherapy and immunotherapy in an elderly patient"],"prefix":"10.3389","volume":"14","author":[{"given":"Justin K. W.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin C. Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy C. Y.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raiden T. S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2545","article-title":"The BRD4-NUT fusion alone drives Malignant transformation of NUT carcinoma","volume":"83","author":"Taylor Durall","year":"2023","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860830","article-title":"NUT carcinoma: Clinicopathologic features, molecular genetics and epigenetics","volume":"12","author":"Moreno","year":"2022","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/hed.27553","article-title":"Sinonasal NUT carcinoma: A consecutive case series and systematic review","volume":"46","author":"Ramesh","year":"2024","journal-title":"Head Neck"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30242","article-title":"Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck","volume":"122","author":"Chau","year":"2016","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7262","article-title":"A sinonasal NUT midline carcinoma in an 84-year-old man undergoing radiation and proton therapy","volume":"11","author":"Zhang","year":"2023","journal-title":"Clin Case Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01449-x","article-title":"Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma","volume":"15","author":"Xie","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.10.016","article-title":"Prolonged disease control on nivolumab for primary pulmonary NUT carcinoma","volume":"22","author":"Davis","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.36401\/JIPO-23-19","article-title":"Sustained clinical response to immunotherapy followed by BET inhibitor in a patient with unresectable sinonasal NUT carcinoma","volume":"7","author":"Herbison","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1083_22","article-title":"Immunotherapy experience in sinonasal NUT midline carcinoma, case report","volume":"20","author":"Caner","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-020-01254-9","article-title":"NUT carcinoma arising from the parotid gland: A case report and review of the literature","volume":"15","author":"Saik","year":"2021","journal-title":"Head Neck Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1094770","article-title":"The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report","volume":"13","author":"Fu","year":"2023","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1089\/ct.2021;33.38-47","article-title":"NUT carcinoma of the thyroid: An unusual case with a complete response to treatment","volume":"33","author":"Kuo","year":"2021","journal-title":"Clin Thyroidol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/PAI.0000000000000781","article-title":"Tumor mutation burden and checkpoint immunotherapy markers in NUT Midline carcinoma","volume":"28","author":"He","year":"2020","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7150\/thno.43539","article-title":"Radiation-induced small extracellular vesicles as \u201ccarriages\u201d promote tumor antigen release and trigger antitumor immunity","volume":"10","author":"Lin","year":"2020","journal-title":"Theranostics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0986","article-title":"PD-1\/PD-L1 immune checkpoint inhibition with radiation in bladder cancer: In situ and abscopal effects","volume":"19","author":"Rompr\u00e9-Brodeur","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial: Results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.690115","article-title":"Immunotherapy and targeting the tumor microenvironment: Current place and new insights in primary pulmonary NUT carcinoma","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27502","article-title":"Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy","volume":"45","author":"Guller","year":"2023","journal-title":"Head Neck"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100577","article-title":"The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression","volume":"7","author":"Kim","year":"2022","journal-title":"ESMO Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100441","article-title":"Clinical outcomes of patients with metastatic NSCLC after discontinuation of immunotherapy because of immune-related adverse effects","volume":"4","author":"Lievense","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2021.06.009","article-title":"Survival outcomes following discontinuation of ipilimumab and nivolumab for advanced melanoma in a population-based cohort","volume":"33","author":"Ksienski","year":"2021","journal-title":"Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx363.021","article-title":"Baseline gut microbiota in metastatic melanoma patients treated with ipilimumab: Relation with clinical response and colitis","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz094","article-title":"An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) Midline carcinoma: Analysis of 124 patients","volume":"4","author":"Chau","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41419-022-05204-x","article-title":"BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia","volume":"13","author":"Zhong","year":"2022","journal-title":"Cell Death Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7150\/jca.69375","article-title":"BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC","volume":"13","author":"Wang","year":"2022","journal-title":"J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152955","article-title":"Targeting radioresistance and replication fork stability in prostate cancer","volume":"7","author":"Li","year":"2022","journal-title":"JCI Insight"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1412070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:32:39Z","timestamp":1736209959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1412070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":30,"alternative-id":["10.3389\/fonc.2024.1412070"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1412070","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1412070"}}